Description
solution developed by Love Cosmedical for the reduction of localized adipose tissue in the facial and submental regions. The product belongs to the category of injectable lipolytic treatments and is formulated to target stubborn fat deposits that may persist despite diet and exercise efforts.
The primary active ingredient is sodium deoxycholate 0.5%, a bile acid derivative that disrupts adipocyte cell membranes, promoting the breakdown of localized fat cells. The formulation also contains caffeine and equisetum (horsetail extract), which are included to support lipid metabolism and tissue drainage processes.
DesoFace is intended for aesthetic contouring of facial areas affected by localized fat accumulation, particularly the cheeks, jowls, neck, and submental region (double chin). It is designed as a non-surgical alternative for facial contour refinement and localized fat reduction when administered by appropriately qualified healthcare professionals.
What DesoFace 5 x 10 ml Is Similar To
DesoFace belongs to the same category of lipolytic injectables as Kybella®, Aqualyx®, and DesoBody®, although each product differs in concentration, treatment indications, and treatment areas.
Like Kybella®, DesoFace uses a deoxycholate-based mechanism to disrupt adipocyte membranes and reduce localized fat deposits. However, Kybella is specifically approved for submental fat reduction in certain markets and follows different treatment protocols.
Compared with DesoBody, DesoFace contains a lower sodium deoxycholate concentration (0.5%), making it specifically intended for smaller and more delicate facial treatment areas. DesoBody contains a higher concentration and is generally positioned for larger body areas.
Aqualyx is also used for localized fat reduction but differs in formulation and manufacturer guidance. Selection between products should always be based on practitioner assessment, treatment goals, and product-specific instructions.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to publicly available manufacturer-aligned information, DesoFace may be used for the treatment of:
-
Double chin (submental fat)
-
Cheeks
-
Jowls
-
Neck fat
-
Facial contouring areas with localized adiposity
Some distributors also reference use around the lower facial contour and selected facial regions where localized fat deposits are present.
Usage / Administration (IFU-Only Section)
-
Injection depth: Not provided by manufacturer in publicly accessible documentation.
-
Volume per injection point: Not provided by manufacturer.
-
Needle gauge: Not provided by manufacturer.
-
Dosage per treatment area: Manufacturer-aligned sources indicate approximately ½ vial (5 ml) per 5 × 5 cm area of localized adiposity.
-
Treatment frequency: Typically every 5–6 weeks according to manufacturer-aligned guidance.
-
Number of sessions: Not provided by manufacturer. Publicly available sources indicate visible results may occur after the first or second treatment, but the total number of sessions should be determined by the treating professional.
-
Professional-use statement: DesoFace should only be administered by qualified medical professionals using appropriate aseptic techniques and according to local regulations and manufacturer instructions.
Ingredient List
Active Ingredients
-
Sodium Deoxycholate – 0.5%
-
Caffeine
-
Equisetum (Horsetail Extract)
Excipients
-
Not fully disclosed in publicly available manufacturer documentation.
Hyaluronic Acid
-
Not applicable.
Lidocaine
-
No lidocaine reported in publicly available product information.
Presentation & Longevity
Packaging
-
5 × 10 ml vials per pack.
Storage
-
Store between 2°C and 25°C.
Longevity
Manufacturer-aligned sources state that destroyed adipocytes do not regenerate; therefore, results may be long-lasting when body weight remains stable.
However, the manufacturer does not provide a specific clinical longevity range.
Longevity: not provided by manufacturer.
Shelf Life
-
Not provided by manufacturer in publicly available documentation.
Safety Notes / Contraindications
Users should always consult the latest manufacturer instructions before treatment.
Important precautions include:
-
Contraindicated in patients with known hypersensitivity to any component of the formulation.
-
Do not use in areas with active infection, inflammation, or compromised skin integrity.
-
Administration into non-target tissues may increase the risk of adverse reactions.
-
Temporary swelling, tenderness, bruising, redness, and localized discomfort may occur following treatment.
It is important to note that desoface swelling is commonly reported as a temporary post-treatment response and should be assessed and managed by the treating practitioner according to clinical protocols.
Regulatory Status
-
Manufacturer: Love Cosmedical SRL (Italy).
-
CE Marked medical-aesthetic product according to distributor and manufacturer-aligned documentation.
-
Professional-use product.
UKCA status: Verify via current manufacturer IFU, distributor documentation, or product packaging.
FDA status: No publicly accessible FDA approval information identified for DesoFace.
Frequently Asked Questions
1. How does DesoFace work?
DesoFace contains sodium deoxycholate, which disrupts adipocyte cell membranes. Once fat cells are broken down, their contents are gradually processed and removed through the body’s natural metabolic pathways. The formulation also includes caffeine and horsetail extract, which are commonly incorporated into lipolytic formulations.
2. What areas can be treated with DesoFace?
Publicly available manufacturer-aligned information identifies the cheeks, double chin, jowls, and neck as primary treatment areas. These regions are often selected when localized adiposity affects facial definition and contour. Treatment suitability should always be determined by a qualified healthcare professional.
3. Is swelling normal after treatment?
Yes. Temporary desoface swelling, redness, tenderness, and bruising are commonly reported local reactions following lipolytic treatments. The degree and duration vary according to treatment area, patient characteristics, and treatment volume. Patients should follow all aftercare instructions provided by their practitioner.
4. How many treatment sessions are usually required?
The manufacturer does not specify a fixed number of sessions in publicly available documentation. Manufacturer-aligned sources indicate treatments are commonly spaced every 5–6 weeks, and visible improvement may occur after the first or second treatment session.
5. How does DesoFace compare with DesoBody?
Both products belong to the Love Cosmedical lipolytic range and use sodium deoxycholate as their primary active ingredient. DesoFace contains 0.5% sodium deoxycholate and is intended for facial areas, whereas DesoBody contains a higher concentration and is intended for larger body areas. Product selection should be based on the treatment area and practitioner assessment.
